Flow Diagram

Patient ≥ 1 y and ≤ 16 y presents with clinical and laboratory evidence of T cell deficiency

Consent and Study inclusion

Study coordination verifies study eligibility

Visit 1
- severe events retrospective
- immunology baseline
- documentation of HSCT decision

HSCT group 1

No HSCT group 2

PEG-ADA Gene therapy

Yearly visits (severe events, immunology)
6 mo, 12 mo post HSCT visit
(engraftment, reconstitution)

HSCT outcome

1. Survival
2. Time point of HSCT
3. Frequency of major infections and / or immune dysregulation